CUDC-101 is primarily utilized in cancer research and therapy development due to its unique ability to simultaneously inhibit multiple signaling pathways involved in tumor growth and survival. It targets histone deacetylase (HDAC), epidermal growth factor receptor (EGFR), and human epidermal growth factor receptor 2 (HER2), making it a promising candidate for treating cancers that are resistant to single-target therapies. Its application is particularly relevant in studies focusing on solid tumors, such as breast, lung, and pancreatic cancers, where these pathways are often dysregulated. Researchers are also exploring its potential in combination therapies to enhance efficacy and overcome drug resistance. Additionally, CUDC-101 is being investigated for its role in inducing apoptosis and inhibiting angiogenesis, which are critical for halting cancer progression.